Current limitations across pricing, coverage, and payment frameworks are lasering out and hindering global access to many approved cell and gene therapies (CGTs). The Cell & Gene Therapy Pricing & Reimbursement Summit is here to change that. 

Returned for its 2nd edition, this unique summit shared real-world case studies of success and setback in ensuring patients can access CGTs to spearhead reform in this thorny landscape.

Industry-led discussions centered on innovative payment models being developed and applied, new stop-loss and reinsurance programs, and how leading companies are ensuring coverage and uptake of their commercialized therapies. You have left with actionable learnings from recent CMS policy changes, including the Access Model, Medicaid Drug Rebate Program Final Rule, and proposed increases to inpatient CAR-T reimbursement rates.

Leaders from biopharma, government agencies, commercial payers, academics, and market access-specialist service providers came together to align on the current market access strategy and policy challenges that had been hindering widespread adoption of these ground-breaking therapies. The summit aimed to enhance your payer coverage and improve patient access.